JP5560393B2 - 心筋細胞系列細胞への霊長類多能性幹細胞の分化 - Google Patents
心筋細胞系列細胞への霊長類多能性幹細胞の分化 Download PDFInfo
- Publication number
- JP5560393B2 JP5560393B2 JP2008518339A JP2008518339A JP5560393B2 JP 5560393 B2 JP5560393 B2 JP 5560393B2 JP 2008518339 A JP2008518339 A JP 2008518339A JP 2008518339 A JP2008518339 A JP 2008518339A JP 5560393 B2 JP5560393 B2 JP 5560393B2
- Authority
- JP
- Japan
- Prior art keywords
- cells
- bmp
- cell
- activin
- culture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 210000004027 cell Anatomy 0.000 title claims description 439
- 210000004413 cardiac myocyte Anatomy 0.000 title claims description 103
- 241000288906 Primates Species 0.000 title description 64
- 210000001778 pluripotent stem cell Anatomy 0.000 title description 52
- 230000004069 differentiation Effects 0.000 title description 43
- 238000000034 method Methods 0.000 claims description 90
- 239000002609 medium Substances 0.000 claims description 59
- 108010059616 Activins Proteins 0.000 claims description 39
- 239000000488 activin Substances 0.000 claims description 39
- 238000012258 culturing Methods 0.000 claims description 37
- 102100026818 Inhibin beta E chain Human genes 0.000 claims description 36
- 210000002216 heart Anatomy 0.000 claims description 23
- 108010023082 activin A Proteins 0.000 claims description 16
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 claims description 13
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 claims description 13
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 10
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims description 10
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 claims description 9
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 claims description 9
- 210000002242 embryoid body Anatomy 0.000 claims description 9
- 239000012679 serum free medium Substances 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 claims description 2
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 claims description 2
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 37
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 37
- 229940112869 bone morphogenetic protein Drugs 0.000 description 37
- 102100036859 Troponin I, cardiac muscle Human genes 0.000 description 33
- 101710128251 Troponin I, cardiac muscle Proteins 0.000 description 33
- 210000001519 tissue Anatomy 0.000 description 28
- 210000002966 serum Anatomy 0.000 description 23
- 239000012091 fetal bovine serum Substances 0.000 description 19
- 239000000523 sample Substances 0.000 description 19
- 210000001671 embryonic stem cell Anatomy 0.000 description 18
- 210000000130 stem cell Anatomy 0.000 description 18
- 239000000243 solution Substances 0.000 description 17
- 238000010186 staining Methods 0.000 description 17
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 16
- 102000004142 Trypsin Human genes 0.000 description 16
- 108090000631 Trypsin Proteins 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- 239000012588 trypsin Substances 0.000 description 16
- 108010010803 Gelatin Proteins 0.000 description 14
- 230000000747 cardiac effect Effects 0.000 description 14
- 239000008273 gelatin Substances 0.000 description 14
- 229920000159 gelatin Polymers 0.000 description 14
- 235000019322 gelatine Nutrition 0.000 description 14
- 235000011852 gelatine desserts Nutrition 0.000 description 14
- 108010082117 matrigel Proteins 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 13
- 238000007792 addition Methods 0.000 description 12
- 239000000872 buffer Substances 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 239000000725 suspension Substances 0.000 description 11
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 10
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 10
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 10
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 10
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 239000006285 cell suspension Substances 0.000 description 10
- 238000000926 separation method Methods 0.000 description 10
- 230000037020 contractile activity Effects 0.000 description 9
- 239000001963 growth medium Substances 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 239000012583 B-27 Supplement Substances 0.000 description 8
- 241000283707 Capra Species 0.000 description 8
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 8
- 102000005604 Myosin Heavy Chains Human genes 0.000 description 8
- 239000011324 bead Substances 0.000 description 8
- 239000003102 growth factor Substances 0.000 description 8
- 238000012216 screening Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 108010084498 Myosin Heavy Chains Proteins 0.000 description 7
- 239000011575 calcium Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 210000002950 fibroblast Anatomy 0.000 description 7
- 210000002064 heart cell Anatomy 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 101800001288 Atrial natriuretic factor Proteins 0.000 description 6
- 102400001282 Atrial natriuretic peptide Human genes 0.000 description 6
- 101800001890 Atrial natriuretic peptide Proteins 0.000 description 6
- 102000029816 Collagenase Human genes 0.000 description 6
- 108060005980 Collagenase Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 229960002424 collagenase Drugs 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 230000002107 myocardial effect Effects 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 229930040373 Paraformaldehyde Natural products 0.000 description 5
- 238000010240 RT-PCR analysis Methods 0.000 description 5
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 5
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 5
- 230000008602 contraction Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 229920002866 paraformaldehyde Polymers 0.000 description 5
- 108091033319 polynucleotide Proteins 0.000 description 5
- 102000040430 polynucleotide Human genes 0.000 description 5
- 239000002157 polynucleotide Substances 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 239000013589 supplement Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 230000002861 ventricular Effects 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 108091023040 Transcription factor Proteins 0.000 description 4
- 102000040945 Transcription factor Human genes 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 210000002308 embryonic cell Anatomy 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 210000001654 germ layer Anatomy 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 210000003716 mesoderm Anatomy 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- UBWXUGDQUBIEIZ-UHFFFAOYSA-N (13-methyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl) 3-phenylpropanoate Chemical compound CC12CCC(C3CCC(=O)C=C3CC3)C3C1CCC2OC(=O)CCC1=CC=CC=C1 UBWXUGDQUBIEIZ-UHFFFAOYSA-N 0.000 description 3
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 3
- 102000005606 Activins Human genes 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 108010085895 Laminin Proteins 0.000 description 3
- 101100013973 Mus musculus Gata4 gene Proteins 0.000 description 3
- 101150114527 Nkx2-5 gene Proteins 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 3
- 101100460507 Xenopus laevis nkx-2.5 gene Proteins 0.000 description 3
- 230000001464 adherent effect Effects 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000010009 beating Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 239000013611 chromosomal DNA Substances 0.000 description 3
- 239000003636 conditioned culture medium Substances 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 210000003754 fetus Anatomy 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000004217 heart function Effects 0.000 description 3
- 238000003365 immunocytochemistry Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 210000002235 sarcomere Anatomy 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 230000003595 spectral effect Effects 0.000 description 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 description 2
- 102100028728 Bone morphogenetic protein 1 Human genes 0.000 description 2
- 108090000654 Bone morphogenetic protein 1 Proteins 0.000 description 2
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 description 2
- 102000000905 Cadherin Human genes 0.000 description 2
- 108050007957 Cadherin Proteins 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 208000026740 Congenital cardiovascular disease Diseases 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 2
- 102100037362 Fibronectin Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- 102000004862 Gastrin releasing peptide Human genes 0.000 description 2
- 108090001053 Gastrin releasing peptide Proteins 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 101000595198 Homo sapiens Podocalyxin Proteins 0.000 description 2
- 101000655352 Homo sapiens Telomerase reverse transcriptase Proteins 0.000 description 2
- 102000036675 Myoglobin Human genes 0.000 description 2
- 108010062374 Myoglobin Proteins 0.000 description 2
- 108050000637 N-cadherin Proteins 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 102000002584 Octamer Transcription Factor-3 Human genes 0.000 description 2
- 108010068425 Octamer Transcription Factor-3 Proteins 0.000 description 2
- 102100036031 Podocalyxin Human genes 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 102000004987 Troponin T Human genes 0.000 description 2
- 108090001108 Troponin T Proteins 0.000 description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 2
- 108010031318 Vitronectin Proteins 0.000 description 2
- 102100035140 Vitronectin Human genes 0.000 description 2
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 2
- 229960003459 allopurinol Drugs 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000002469 basement membrane Anatomy 0.000 description 2
- 108010014494 beta-1 Adrenergic Receptors Proteins 0.000 description 2
- 102000016967 beta-1 Adrenergic Receptors Human genes 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000001143 conditioned effect Effects 0.000 description 2
- 210000000555 contractile cell Anatomy 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000007831 electrophysiology Effects 0.000 description 2
- 238000002001 electrophysiology Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- PUBCCFNQJQKCNC-XKNFJVFFSA-N gastrin-releasingpeptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)C(C)C)[C@@H](C)O)C(C)C)[C@@H](C)O)C(C)C)C1=CNC=N1 PUBCCFNQJQKCNC-XKNFJVFFSA-N 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000009067 heart development Effects 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 210000005003 heart tissue Anatomy 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- -1 polypropylene Polymers 0.000 description 2
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 229940126586 small molecule drug Drugs 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 229940116269 uric acid Drugs 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- XNCSCQSQSGDGES-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]propyl-(carboxymethyl)amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)C(C)CN(CC(O)=O)CC(O)=O XNCSCQSQSGDGES-UHFFFAOYSA-N 0.000 description 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 1
- 102000010825 Actinin Human genes 0.000 description 1
- 108010063503 Actinin Proteins 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 101000993093 Arabidopsis thaliana Heat stress transcription factor B-2a Proteins 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 101100124874 Caenorhabditis elegans hsf-1 gene Proteins 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 108010002947 Connectin Proteins 0.000 description 1
- 102000004726 Connectin Human genes 0.000 description 1
- 102000010970 Connexin Human genes 0.000 description 1
- 108050001175 Connexin Proteins 0.000 description 1
- 102000001045 Connexin 43 Human genes 0.000 description 1
- 108010069241 Connexin 43 Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 208000001778 Coronary Occlusion Diseases 0.000 description 1
- 206010011086 Coronary artery occlusion Diseases 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 102000006312 Cyclin D2 Human genes 0.000 description 1
- 108010058544 Cyclin D2 Proteins 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 101000953562 Dendroaspis angusticeps Kunitz-type serine protease inhibitor homolog calcicludine Proteins 0.000 description 1
- 101000723297 Dendroaspis polylepis polylepis Calciseptin Proteins 0.000 description 1
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 1
- 102100036912 Desmin Human genes 0.000 description 1
- 108010044052 Desmin Proteins 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 description 1
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 101150094793 Hes3 gene Proteins 0.000 description 1
- 101150029234 Hes5 gene Proteins 0.000 description 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 101000766306 Homo sapiens Serotransferrin Proteins 0.000 description 1
- 101000843556 Homo sapiens Transcription factor HES-1 Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- BAQCROVBDNBEEB-UBYUBLNFSA-N Metrizamide Chemical compound CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C(=O)N[C@@H]2[C@H]([C@H](O)[C@@H](CO)OC2O)O)=C1I BAQCROVBDNBEEB-UBYUBLNFSA-N 0.000 description 1
- 101100369076 Mus musculus Tdgf1 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102100031790 Myelin expression factor 2 Human genes 0.000 description 1
- 101710107751 Myelin expression factor 2 Proteins 0.000 description 1
- 108010056785 Myogenin Proteins 0.000 description 1
- 102100032970 Myogenin Human genes 0.000 description 1
- 101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 239000005700 Putrescine Substances 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 101100016889 Rattus norvegicus Hes2 gene Proteins 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 102100032938 Telomerase reverse transcriptase Human genes 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 102100030798 Transcription factor HES-1 Human genes 0.000 description 1
- 241000009298 Trigla lyra Species 0.000 description 1
- 102000005937 Tropomyosin Human genes 0.000 description 1
- 108010030743 Tropomyosin Proteins 0.000 description 1
- 102000004903 Troponin Human genes 0.000 description 1
- 108090001027 Troponin Proteins 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 108010092464 Urate Oxidase Proteins 0.000 description 1
- 108010051583 Ventricular Myosins Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000036982 action potential Effects 0.000 description 1
- 108010023079 activin B Proteins 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- 229940126157 adrenergic receptor agonist Drugs 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 238000011316 allogeneic transplantation Methods 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 108010016628 ameroid Proteins 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000036815 beta tubulin Diseases 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000008081 blood perfusion Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000005242 cardiac chamber Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000002057 chronotropic effect Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 230000002559 cytogenic effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 210000005045 desmin Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 210000003981 ectoderm Anatomy 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 210000001900 endoderm Anatomy 0.000 description 1
- 210000004039 endoderm cell Anatomy 0.000 description 1
- 210000005168 endometrial cell Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 210000003953 foreskin Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 210000003976 gap junction Anatomy 0.000 description 1
- 238000012248 genetic selection Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000037183 heart physiology Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 229960001317 isoprenaline Drugs 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 241001515942 marmosets Species 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000031864 metaphase Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229960000554 metrizamide Drugs 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000005868 ontogenesis Effects 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000004526 pharmaceutical effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 231100000188 sister chromatid exchange Toxicity 0.000 description 1
- 210000002363 skeletal muscle cell Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000009168 stem cell therapy Methods 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 238000009580 stem-cell therapy Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002948 striated muscle cell Anatomy 0.000 description 1
- 230000016166 striated muscle contraction Effects 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 229940005267 urate oxidase Drugs 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0657—Cardiomyocytes; Heart cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/105—Insulin-like growth factors [IGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/54—Collagen; Gelatin
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69314105P | 2005-06-22 | 2005-06-22 | |
| US60/693,141 | 2005-06-22 | ||
| PCT/US2006/024060 WO2007002136A2 (en) | 2005-06-22 | 2006-06-20 | Differentiation of primate pluripotent stem cells to cardiomyocyte-lineage cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013135917A Division JP2013215206A (ja) | 2005-06-22 | 2013-06-28 | 心筋細胞系列細胞への霊長類多能性幹細胞の分化 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008543338A JP2008543338A (ja) | 2008-12-04 |
| JP2008543338A5 JP2008543338A5 (enExample) | 2009-04-16 |
| JP5560393B2 true JP5560393B2 (ja) | 2014-07-23 |
Family
ID=37595761
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008518339A Expired - Fee Related JP5560393B2 (ja) | 2005-06-22 | 2006-06-20 | 心筋細胞系列細胞への霊長類多能性幹細胞の分化 |
| JP2013135917A Pending JP2013215206A (ja) | 2005-06-22 | 2013-06-28 | 心筋細胞系列細胞への霊長類多能性幹細胞の分化 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013135917A Pending JP2013215206A (ja) | 2005-06-22 | 2013-06-28 | 心筋細胞系列細胞への霊長類多能性幹細胞の分化 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US9062289B2 (enExample) |
| EP (1) | EP1910518B1 (enExample) |
| JP (2) | JP5560393B2 (enExample) |
| KR (2) | KR20130099253A (enExample) |
| CN (1) | CN101228264B (enExample) |
| AU (1) | AU2006262329B2 (enExample) |
| CA (1) | CA2611809C (enExample) |
| GB (1) | GB2441718B (enExample) |
| IL (1) | IL187611A (enExample) |
| WO (1) | WO2007002136A2 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12316846B2 (en) | 2011-06-16 | 2025-05-27 | Dolby Video Compression, Llc | Entropy coding of motion vector differences |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2412383A1 (en) * | 2006-07-28 | 2012-02-01 | Children's Memorial Hospital | Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells |
| US8106004B2 (en) * | 2006-07-28 | 2012-01-31 | Children's Memorial Hospital | Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells |
| WO2009120762A2 (en) | 2008-03-27 | 2009-10-01 | Mount Sinai School Of Medicine Of New York University | Human cardiovascular progenitor cells |
| CA2777552C (en) | 2009-10-19 | 2019-05-21 | Cellular Dynamics International, Inc. | Cardiomyocyte production |
| US9181529B2 (en) | 2010-10-19 | 2015-11-10 | Cellular Dynamics International, Inc. | Titration of differentiation medium components |
| JP6090855B2 (ja) | 2010-11-17 | 2017-03-08 | 国立大学法人京都大学 | 心筋細胞および/または心筋前駆細胞増殖剤ならびに心筋細胞および/または心筋前駆細胞の増殖方法 |
| US20140329314A1 (en) | 2011-03-29 | 2014-11-06 | Christopher O'Sullivan | Enriched populations of cardiomyocyte lineage cells from pluripotent stem cells |
| US9487752B2 (en) | 2011-03-30 | 2016-11-08 | Cellular Dynamics International, Inc. | Priming of pluripotent stem cells for neural differentiation |
| JP5840855B2 (ja) | 2011-03-30 | 2016-01-06 | 学校法人東京女子医科大学 | 胚性幹細胞から心筋シートを製造する方法 |
| US9164093B2 (en) | 2011-03-31 | 2015-10-20 | Iheart Japan Corporation | Cardiomyocyte marker |
| KR101966208B1 (ko) | 2011-07-21 | 2019-04-09 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 환자로부터 유도 만능 줄기 세포들로부터의 심근 세포 및 그 사용 방법 |
| GB201121101D0 (en) * | 2011-12-08 | 2012-01-18 | Nhs Blood & Transplant | A method of preparing isolated cells and uses |
| EP2826855B1 (en) | 2012-03-15 | 2018-08-29 | iHeart Japan Corporation | Myocardial sheet |
| JP6373253B2 (ja) | 2012-07-17 | 2018-08-15 | 国立大学法人京都大学 | 新規心筋細胞マーカー |
| JP6429280B2 (ja) | 2013-05-14 | 2018-11-28 | 国立大学法人京都大学 | 効率的な心筋細胞の誘導方法 |
| CN105247041B (zh) | 2013-05-31 | 2018-04-20 | 爱心细胞有限公司 | 组入有水凝胶的层叠细胞膜片 |
| WO2014192312A1 (ja) * | 2013-05-31 | 2014-12-04 | 国立大学法人 東京医科歯科大学 | 正常な内向きのカリウム電流特性を有するiPS細胞由来心筋モデル細胞 |
| KR102423106B1 (ko) | 2013-06-11 | 2022-07-21 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | SC-β 세포 및 조성물 그리고 그 생성 방법 |
| EP3121276B1 (en) | 2014-03-20 | 2019-04-17 | Kyoto University | Cardiomyocyte sorting method |
| EP3140395B1 (en) * | 2014-05-06 | 2020-01-22 | F. Hoffmann-La Roche AG | Method for differentiation of pluripotent stem cells into cardiomyocytes |
| JP6265515B2 (ja) * | 2014-09-16 | 2018-01-24 | 国立大学法人大阪大学 | 多能性幹細胞由来心筋細胞集団の製造方法 |
| WO2016100930A1 (en) | 2014-12-18 | 2016-06-23 | President And Fellows Of Harvard College | Methods for generating stem cell-derived b cells and methods of use thereof |
| WO2016100909A1 (en) | 2014-12-18 | 2016-06-23 | President And Fellows Of Harvard College | METHODS FOR GENERATING STEM CELL-DERIVED β CELLS AND USES THEREOF |
| WO2016100898A1 (en) | 2014-12-18 | 2016-06-23 | President And Fellows Of Harvard College | Serum-free in vitro directed differentiation protocol for generating stem cell-derived b cells and uses thereof |
| US10556388B2 (en) * | 2015-04-22 | 2020-02-11 | Eastman Chemical Company | Polyester-based tape composites for wood reinforcement |
| HK1254190A1 (zh) | 2015-05-08 | 2019-07-12 | President And Fellows Of Harvard College | 通用供体干细胞和相关方法 |
| AU2018370029B2 (en) | 2017-11-15 | 2024-11-07 | Vertex Pharmaceuticals Incorporated | Islet cell manufacturing compositions and methods of use |
| WO2019189545A1 (ja) | 2018-03-30 | 2019-10-03 | 国立大学法人京都大学 | 細胞の製造方法 |
| US11401264B2 (en) | 2018-03-30 | 2022-08-02 | Orizuru Therapeutics, Inc. | Heterocyclic compound |
| WO2019189554A1 (ja) | 2018-03-30 | 2019-10-03 | 国立大学法人京都大学 | 心筋細胞成熟促進剤 |
| EP3833365A4 (en) | 2018-08-10 | 2022-05-11 | Vertex Pharmaceuticals Incorporated | Stem cell derived islet differentiation |
| TWI837161B (zh) | 2018-08-10 | 2024-04-01 | 日商武田藥品工業股份有限公司 | 陽離子性脂質 |
| CN112639111B (zh) | 2018-08-10 | 2023-07-21 | 国立大学法人京都大学 | 使用阳离子性脂质的转染心肌细胞的方法 |
| EP4017508A1 (en) | 2019-08-23 | 2022-06-29 | Sana Biotechnology, Inc. | Cd24 expressing cells and uses thereof |
| MX2023001831A (es) | 2020-08-13 | 2023-06-29 | Sana Biotechnology Inc | Métodos de tratamiento de pacientes sensibilizados con células hipoinmunogénicas y métodos y composiciones asociados. |
| KR20240013135A (ko) | 2021-05-27 | 2024-01-30 | 사나 바이오테크놀로지, 인크. | 조작된 hla-e 또는 hla-g를 포함하는 저면역원성 세포 |
| AU2022309875A1 (en) | 2021-07-14 | 2024-01-25 | Sana Biotechnology, Inc. | Altered expression of y chromosome-linked antigens in hypoimmunogenic cells |
| EP4384598A1 (en) | 2021-08-11 | 2024-06-19 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions |
| WO2023019225A2 (en) | 2021-08-11 | 2023-02-16 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions |
| EP4384544A1 (en) | 2021-08-11 | 2024-06-19 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy |
| IL310702A (en) | 2021-08-11 | 2024-04-01 | Sana Biotechnology Inc | Inducible systems for altering gene expression in hypoimmunogenic cells |
| KR20230073749A (ko) | 2021-11-19 | 2023-05-26 | 주식회사 로킷헬스케어 | 박동형 심근 패치의 제조방법 및 이를 이용하여 제조된 박동형 심근 패치 |
| WO2023183313A1 (en) | 2022-03-22 | 2023-09-28 | Sana Biotechnology, Inc. | Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods |
| WO2024243236A2 (en) | 2023-05-22 | 2024-11-28 | Sana Biotechnology, Inc. | Methods of delivery of islet cells and related methods |
| WO2025054202A1 (en) | 2023-09-05 | 2025-03-13 | Sana Biotechnology, Inc. | Method of screening a sample comprising a transgene with a unique barcode |
| WO2025151838A1 (en) | 2024-01-12 | 2025-07-17 | Sana Biotechnology, Inc. | Safety switches to control in vitro and in vivo proliferation of cell therapy products |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4491632A (en) | 1979-10-22 | 1985-01-01 | The Massachusetts General Hospital | Process for producing antibodies to hepatitis virus and cell lines therefor |
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| DE3167442D1 (en) | 1980-07-07 | 1985-01-10 | Nat Res Dev | Improvements in or relating to cell lines |
| GB2197915B (en) | 1986-11-19 | 1990-11-14 | Rolls Royce Plc | Improvements in or relating to fluid bearings |
| WO1992013066A1 (en) | 1991-01-24 | 1992-08-06 | Loyola University Of Chicago | Mammalian cardiac myocyte cell line |
| US5543318A (en) | 1991-06-12 | 1996-08-06 | Smith; David A. | Method of isolation, culture and proliferation of human atrial myocytes |
| US5523226A (en) | 1993-05-14 | 1996-06-04 | Biotechnology Research And Development Corp. | Transgenic swine compositions and methods |
| US5602301A (en) | 1993-11-16 | 1997-02-11 | Indiana University Foundation | Non-human mammal having a graft and methods of delivering protein to myocardial tissue |
| US6015671A (en) | 1995-06-07 | 2000-01-18 | Indiana University Foundation | Myocardial grafts and cellular compositions |
| DE4441327C1 (de) | 1994-11-22 | 1995-11-09 | Inst Pflanzengenetik & Kultur | Embryonale Herzmuskelzellen, ihre Herstellung und ihre Verwendung |
| US5843780A (en) | 1995-01-20 | 1998-12-01 | Wisconsin Alumni Research Foundation | Primate embryonic stem cells |
| ATE322282T1 (de) | 1996-08-16 | 2006-04-15 | Mcw Res Found Inc | Knochen morphogenetisches protein und fibroblasten wachstumsfaktor enthaltende zusammensetzungen und methoden zur induzierung der kardiogenese |
| US20020061837A1 (en) * | 1996-09-05 | 2002-05-23 | Lough John W. | Bone morphogenetic protein and fibroblast growth factor compositions and methods for the induction of cardiogenesis |
| US6261836B1 (en) | 1996-10-01 | 2001-07-17 | Geron Corporation | Telomerase |
| EP0986635A4 (en) | 1997-01-10 | 2001-11-07 | Life Technologies Inc | SERUM SUBSTITUTE FOR EMBRYONIC STEM CELLS |
| US6331406B1 (en) | 1997-03-31 | 2001-12-18 | The John Hopkins University School Of Medicine | Human enbryonic germ cell and methods of use |
| US6099832A (en) | 1997-05-28 | 2000-08-08 | Genzyme Corporation | Transplants for myocardial scars |
| US6110459A (en) | 1997-05-28 | 2000-08-29 | Mickle; Donald A. G. | Transplants for myocardial scars and methods and cellular preparations |
| DK1007631T4 (da) | 1997-07-14 | 2009-04-27 | Osiris Therapeutics Inc | Hjertemuskelregeneration ved anvendelse af mesenkymale stamceller |
| EP1025204A4 (en) | 1997-10-23 | 2001-02-28 | Geron Corp | Methods and materials for the growth of primate-derived primordial stem cells |
| DE19755800A1 (de) | 1997-12-16 | 1999-06-17 | Merck Patent Gmbh | Cyclopeptidderivate |
| JP2002507407A (ja) | 1998-03-23 | 2002-03-12 | ザイモジェネティクス,インコーポレイティド | 心臓由来幹細胞 |
| IL138502A0 (en) | 1998-04-09 | 2001-10-31 | Bresagen Ltd | Cell differentiation/ proliferation and maintenaince factor and uses thereof |
| AU5545499A (en) | 1998-07-31 | 2000-02-21 | Genzyme Corporation | Improvement of cardiac function by mesenchymal stem cell transplantation |
| US7410798B2 (en) | 2001-01-10 | 2008-08-12 | Geron Corporation | Culture system for rapid expansion of human embryonic stem cells |
| US6667176B1 (en) | 2000-01-11 | 2003-12-23 | Geron Corporation | cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells |
| US20020168766A1 (en) | 2000-01-11 | 2002-11-14 | Gold Joseph D. | Genetically altered human pluripotent stem cells |
| IL129966A (en) | 1999-05-14 | 2009-12-24 | Technion Res & Dev Foundation | ISOLATED HUMAN EMBRYOID BODIES (hEB) DERIVED FROM HUMAN EMBRYONIC STEM CELLS |
| AU783935B2 (en) | 1999-06-18 | 2006-01-05 | Indiana University Research And Technology Corporation | Cardiomyocytes with enhanced proliferative potential, and methods for preparing and using same |
| EP1221956A2 (en) | 1999-09-30 | 2002-07-17 | McGILL UNIVERSITY | Autologous marrow stem cell (msc) transplantation for myocardial regeneration |
| US6280718B1 (en) | 1999-11-08 | 2001-08-28 | Wisconsin Alumni Reasearch Foundation | Hematopoietic differentiation of human pluripotent embryonic stem cells |
| AU784618B2 (en) | 1999-12-28 | 2006-05-18 | Kyowa Hakko Kogyo Co. Ltd. | Cells capable of differentiating into heart muscle cells |
| US20020142457A1 (en) | 1999-12-28 | 2002-10-03 | Akihiro Umezawa | Cell having the potentiality of differentiation into cardiomyocytes |
| WO2001051610A1 (en) | 2000-01-14 | 2001-07-19 | Bresagen Limited | Ectoderm cell production |
| EP1248834A4 (en) | 2000-01-21 | 2004-03-17 | Univ Johns Hopkins | CELLS FROM HUMAN EMBRYOID BODIES |
| JP2004504807A (ja) | 2000-03-10 | 2004-02-19 | アドヴァンスト リサーチ アンド テクノロジー インスティチュート、インコーポレイティッド | 多分化能細胞および心筋細胞集団、並びに該集団への経路およびその使用 |
| US20020061587A1 (en) | 2000-07-31 | 2002-05-23 | Piero Anversa | Methods and compositions for the repair and/or regeneration of damaged myocardium |
| AU2001283088A1 (en) | 2000-07-31 | 2002-02-25 | New York Medical College | Methods and compositions for the repair and/or regeneration of damaged myocardium |
| AU8617301A (en) | 2000-08-01 | 2002-02-13 | Yissum Res Dev Co | Directed differentiation of embryonic cells |
| US6534052B1 (en) | 2000-09-05 | 2003-03-18 | Yong-Fu Xiao | Cardiac function comprising implantation of embryonic stem cell in which differentiation has been initiated |
| US6607720B1 (en) | 2000-09-05 | 2003-08-19 | Yong-Fu Xiao | Genetically altered mammalian embryonic stem cells, their living progeny, and their therapeutic application for improving cardiac function after myocardial infarction |
| JP2004521877A (ja) | 2000-11-22 | 2004-07-22 | ジェロン コーポレイション | 多能性幹細胞の同種移植片の寛容化 |
| AU2002303343A1 (en) | 2001-04-13 | 2002-10-28 | Anterogen Co., Ltd. | Methods and reagents for cell transplantation |
| US7732199B2 (en) * | 2001-07-12 | 2010-06-08 | Geron Corporation | Process for making transplantable cardiomyocytes from human embryonic stem cells |
| IL159580A0 (en) | 2001-07-12 | 2004-06-01 | Geron Corp | Cells of the cardiomyocyte lineage produced from human pluripotent stem cells |
| IL159895A0 (en) | 2001-07-20 | 2004-06-20 | Technion Res & Dev Foundation | Methods of generating human cardiac cells and tissues and uses thereof |
| AU2002317039B2 (en) | 2001-07-24 | 2007-10-04 | Es Cell International Pte Ltd | Methods of inducing differentiation of stem cells |
| EP1463803B1 (en) | 2001-12-07 | 2018-02-14 | Asterias Biotherapeutics, Inc. | Hematopoietic cells from human embryonic stem cells |
| US8298606B2 (en) | 2002-03-08 | 2012-10-30 | The Regents Of The University Of California | Methods and compositions for stabilizing the myocardium |
| US7148062B2 (en) * | 2002-03-15 | 2006-12-12 | Wicell Research Institute, Inc. | Method for generating primate trophoblasts |
| US7247477B2 (en) | 2002-04-16 | 2007-07-24 | Technion Research & Development Foundation Ltd. | Methods for the in-vitro identification, isolation and differentiation of vasculogenic progenitor cells |
| US6898272B2 (en) * | 2002-08-01 | 2005-05-24 | Spirent Communications | System and method for testing telecommunication devices |
| US7569222B2 (en) | 2002-11-18 | 2009-08-04 | Woerly Stephane | Hydrogel membrane composition and use thereof |
| US20050031598A1 (en) | 2002-12-10 | 2005-02-10 | Shulamit Levenberg | Engineering three-dimensional tissue structures using differentiating embryonic stem cells |
| AU2003901099A0 (en) | 2003-03-11 | 2003-03-27 | Es Cell International Pte Ltd. | Methods of inducing differentiation of stem cells |
| US20030224411A1 (en) | 2003-03-13 | 2003-12-04 | Stanton Lawrence W. | Genes that are up- or down-regulated during differentiation of human embryonic stem cells |
| US20050266554A1 (en) * | 2004-04-27 | 2005-12-01 | D Amour Kevin A | PDX1 expressing endoderm |
| US20050142121A1 (en) | 2003-12-24 | 2005-06-30 | Gold Joseph D. | System for improving acceptance of tissue grafts made from embryonic stem cells |
| EP1725654B1 (en) * | 2004-03-19 | 2019-05-01 | Asterias Biotherapeutics, Inc. | Method for making high purity cardiomyocyte preparations suitable for regenerative medicine |
| US7452718B2 (en) | 2004-03-26 | 2008-11-18 | Geron Corporation | Direct differentiation method for making cardiomyocytes from human embryonic stem cells |
| US20050214938A1 (en) | 2004-03-26 | 2005-09-29 | Gold Joseph D | Cardiac bodies: clusters of spontaneously contracting cells for regenerating cardiac function |
| WO2006138718A2 (en) | 2005-06-17 | 2006-12-28 | Drexel University | Three-dimensional scaffolds for tissue engineering made by processing complex extracts of natural extracellular matrices |
| JP2010530955A (ja) | 2006-12-29 | 2010-09-16 | ユニヴァーシティ オブ ワシントン | 二重機能性非汚染表面および材料 |
| WO2009099555A2 (en) | 2008-01-30 | 2009-08-13 | Corning Incorporated | Synthetic surfaces for culturing cells in chemically defined media |
| US9115238B2 (en) | 2009-05-28 | 2015-08-25 | Corning Incorporated | Swellable synthetic microcarriers for culturing cells |
-
2006
- 2006-06-20 KR KR1020137021754A patent/KR20130099253A/ko not_active Ceased
- 2006-06-20 EP EP06785229.3A patent/EP1910518B1/en not_active Not-in-force
- 2006-06-20 WO PCT/US2006/024060 patent/WO2007002136A2/en not_active Ceased
- 2006-06-20 JP JP2008518339A patent/JP5560393B2/ja not_active Expired - Fee Related
- 2006-06-20 AU AU2006262329A patent/AU2006262329B2/en not_active Ceased
- 2006-06-20 US US11/471,916 patent/US9062289B2/en active Active
- 2006-06-20 GB GB0800264A patent/GB2441718B/en not_active Expired - Fee Related
- 2006-06-20 CN CN200680022866.6A patent/CN101228264B/zh not_active Expired - Fee Related
- 2006-06-20 KR KR1020087001452A patent/KR101529317B1/ko not_active Expired - Fee Related
- 2006-06-20 CA CA2611809A patent/CA2611809C/en not_active Expired - Fee Related
-
2007
- 2007-11-25 IL IL187611A patent/IL187611A/en not_active IP Right Cessation
-
2013
- 2013-06-28 JP JP2013135917A patent/JP2013215206A/ja active Pending
-
2015
- 2015-06-22 US US14/746,599 patent/US20150284684A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12316846B2 (en) | 2011-06-16 | 2025-05-27 | Dolby Video Compression, Llc | Entropy coding of motion vector differences |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007002136A3 (en) | 2007-04-19 |
| JP2013215206A (ja) | 2013-10-24 |
| CN101228264B (zh) | 2017-12-26 |
| JP2008543338A (ja) | 2008-12-04 |
| GB2441718B (en) | 2010-10-06 |
| IL187611A (en) | 2012-12-31 |
| WO2007002136A9 (en) | 2008-03-06 |
| AU2006262329B2 (en) | 2011-04-07 |
| AU2006262329A1 (en) | 2007-01-04 |
| KR20080030026A (ko) | 2008-04-03 |
| EP1910518B1 (en) | 2019-05-08 |
| GB2441718A (en) | 2008-03-12 |
| KR20130099253A (ko) | 2013-09-05 |
| US20150284684A1 (en) | 2015-10-08 |
| KR101529317B1 (ko) | 2015-06-16 |
| CA2611809A1 (en) | 2007-01-04 |
| US9062289B2 (en) | 2015-06-23 |
| HK1109913A1 (zh) | 2008-06-27 |
| WO2007002136A2 (en) | 2007-01-04 |
| EP1910518A2 (en) | 2008-04-16 |
| CA2611809C (en) | 2018-06-19 |
| US20070010012A1 (en) | 2007-01-11 |
| EP1910518A4 (en) | 2015-03-11 |
| GB0800264D0 (en) | 2008-02-13 |
| CN101228264A (zh) | 2008-07-23 |
| IL187611A0 (en) | 2008-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5560393B2 (ja) | 心筋細胞系列細胞への霊長類多能性幹細胞の分化 | |
| JP4971131B2 (ja) | 再生医学に適した高純度心筋細胞調製物を作製するための方法 | |
| US7897389B2 (en) | Direct differentiation method for making cardiomyocytes from human embryonic stem cells | |
| AU2012236707B2 (en) | Enriched populations of cardiomyocyte lineage cells from pluripotent stem cells | |
| US20240139256A1 (en) | Methods for the production of cardiac fibroblasts | |
| US20230078230A1 (en) | Methods for the production of committed cardiac progenitor cells | |
| KR20240150802A (ko) | 인공 세르톨리 세포 및 이의 제조 방법 | |
| IL178006A (en) | Method for making high purity cardiomyocyte preparations suitable for regenerative medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090227 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090227 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100118 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20100118 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100125 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20100212 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111028 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120126 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120202 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120426 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121228 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130222 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130301 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130628 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140310 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20140409 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140409 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5560393 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |